Practice Point Communications

Please refer to the activity landing page for the downloadable slides.Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This podcast will utilize case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC. Launch Date: January 21, 2025Release Date: January 21, 2025Expiration Date: December 31, 2025FACULTYDavid W. Victor III, MDAssociate Professor of Clinical MedicineHouston Methodist Research InstituteThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.Launch Date: January 9, 2025Release Date: January 9, 2025Expiration Date: December 31, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

What's New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Children's HospitalAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In Highlights and Hindsight in CLL, Dr. Matthew Davids will describe the most significant ongoing studies and publications in CLL from 2024 and will detail their impact on the treatment continuum. This activity will enable participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.Launch Date: December 18, 2024Release Date: December 18, 2024Expiration Date: November 30, 2025FACULTYMatthew Davids, MD, MMScDirector of Clinical Research, Division of LymphomaDana-Farber Cancer InstitueThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.Launch Date: December 16, 2024Release Date: December 16, 2024Expiration Date: November 30, 2025FACULTYNaval Daver, MDDirector, Leukemia Research Alliance Program,Professor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.

Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.Launch Date: December 12, 2024Release Date: December 12, 2024Expiration Date: November 30, 2025FACULTYGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren's Hospital Los AngelesThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.Launch Date: December 5, 2024Release Date: December 5, 2024Expiration Date: November 30, 2025FACULTYAditya Bardia, MD, MPH, FASCOAssociate Professor, Medicine, Harvard Medical SchoolAttending Physician, Medical Oncology, Massachusetts General HospitalDana-Farber/Harvard Cancer Center, Boston, MARita Nanda, MDAssociate Professor of MedicineDirector, Breast Oncology ProgramThe University of Chicago Medicine Chicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.Launch Date: December 2, 2024Release Date: December 2, 2024Expiration Date: November 30, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 25, 2024Release Date: November 25 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Vitiligo is a relatively common acquired pigmentation disorder. The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. Moreover, vitiligo can carry significant psychosocial impact. Healthcare providers play a crucial role in shaping patients' understanding of their condition, approach to treatment, and coping mechanisms. In this podcast series, Dr. Raj Chovatiya, along with his patient, will discuss ways to individualized treatment strategies and improve holistic care of patients with vitiligo.Launch Date: November 21, 2024Release Date: November 21, 2024Expiration Date: October 31, 2025FACULTYRaj Chovatiya, MD, PhD, MSCI, FAADClinical Associate ProfessorRosalind Franklin University Chicago Medical SchoolFounder and DirectorCenter for Medical Dermatology + Immunology ResearchChicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/ask-the-expert-emerging-evidence-to-improve-outcomes-in-vitiligo

This podcast features an engaging discussion between Dr. Douglas Dieterich and his patient with long-standing PBC, on the patient's insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: November 21, 2024Release Date: November 21, 2024Expiration Date: October 31, 2025FACULTYDouglas Dieterich, MDDirector, Institute for Liver Medicine at Mount SinaiProfessor of Medicine, Icahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

Despite significant advancements in the management of pulmonary hypertension (PH), several unmet needs remain. Patients continue to face challenges related to symptom control, mental health, and the long-term impacts of both the disease and its treatments. Additionally, there is a critical need for improved global access to care, multidimensional support, and advocacy. In this podcast episode, Dr. Jean Elwing and Dr. Oksana Shlobin discuss these gaps by focusing on the latest updates from the 7th World Symposium on Pulmonary Hypertension (WSPH), offering insights into the latest clinical classifications, risk stratifications, and treatment strategies.This podcast aims to enhance clinical practice by presenting key research findings, new treatment algorithms, and the implications of emerging therapies. The discussion will include advances in multimodality imaging, genetics, and right ventricular function, highlighting how these innovations improve PH diagnosis and patient management. Through an expert-led presentation and interactive Q&A session, participants will gain a comprehensive understanding of how these developments will shape future research and personalized care for PH patients.Launch Date: November 19, 2024Release Date: November 19, 2024Expiration Date: October 31, 2025FACULTYJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiOksana Shlobin, MDMedical Director, Pulmonary Hypertension ProgramDirector of Education and Outreach, Advanced Lung Disease ProgramInova Fairfax HospitalThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-pah-updates-from-the-7th-world-symposium-on-pulmonary-hypertension-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during HIV Drug Therapy, Glasgow 2024.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYAnton Pozniak, MD, FRCPConsultant PhysicianChelsea and Westminster Hospital London UKThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-hiv-drug-therapy-glasgow-2024-1

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during HIV Drug Therapy, Glasgow 2024.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYAnton Pozniak, MD, FRCPConsultant PhysicianChelsea and Westminster Hospital London UKThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-hiv-drug-therapy-glasgow-2024-1

Vitiligo is a relatively common acquired pigmentation disorder. The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. Moreover, vitiligo can carry significant psychosocial impact. Healthcare providers play a crucial role in shaping patients' understanding of their condition, approach to treatment, and coping mechanisms. In this podcast series, Dr. Raj Chovatiya, along with his patient, will discuss ways to individualized treatment strategies and improve holistic care of patients with vitiligo.Launch Date: November 14, 2024Release Date: November 14, 2024Expiration Date: October 31, 2025FACULTYRaj Chovatiya, MD, PhD, MSCI, FAADAssistant Professor of DermatologyNorthwestern University Feinberg School of MedicineChicago, ILThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/ask-the-expert-emerging-evidence-to-improve-outcomes-in-vitiligo

Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.Launch Date: October 31, 2024Release Date: October 31, 2024Expiration Date: September 30, 2025FACULTYAmy Armstrong, MDAssistant Professor of PediatricsDivision of Hematology/OncologyNeurofibromatosis (NF) CenterWashington University School of MedicineSt. Louis, MissouriThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/neurofibromatosis-type-1-related-plexiform-neurofibromas-improving-diagnosis-and-monitoring-while-integrating-ongoing-updates-in-the-treatment-continuum-1

This podcast features an engaging discussion between Dr. David Victor and his patient, with long-standing PBC, on the patient's insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: October 24, 2024Release Date: October 24, 2024Expiration Date: September 30, 2025FACULTYDavid W. Victor III, MDAssociate Professor of Clinical MedicineHouston Methodist Research InstituteAssociate Professor of Clinical MedicineWeill Cornell MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during IDWeek 2024.Launch Date: October 23, 2024Release Date: October 23, 2024Expiration Date: September 30, 2025FACULTYJoseph Eron, MDProfessor of MedicineUniversity of North Carolina at Chapel HillThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-idweek-2024-1

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' podcast episodes from data presented during IDWeek 2024.Launch Date: October 23, 2024Release Date: October 23, 2024Expiration Date: September 30, 2025FACULTYJoseph Eron, MDProfessor of MedicineUniversity of North Carolina at Chapel HillThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-idweek-2024-1

Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1

Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1

Pulmonary hypertension among patients with interstitial lung diseases (PH-ILD) is currently under-recognized and is associated with increased morbidity, mortality, and healthcare burden. Individualized treatment approaches need to be incorporated in the continuum of care to improve early detection, accurate diagnosis, and improved patient outcomes. In this podcast series, Drs. Jean Elwing, Steven Nathan, and Ioana Preston inform and guide on recent insights to screen for, detect, and accurately diagnose PH-ILD. This on-demand audio presentation uses didactic, case-based, and conversational formats to provide practical guidance and increase familiarity with the latest best-practice approaches for treatment and management of PH-ILD, to ultimately improve the quality of life of patients.Launch Date: October 14, 2024Release Date: October 7, 2024Expiration Date: September 30, 2025FACULTYSteven Nathan, MDMedical Director, Advanced Lung Disease and Transplant ProgramInova Fairfax HospitalJean Elwing, MDProfessor of MedicineDirector, Pulmonary Hypertension ProgramUniversity of CincinnatiIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/expert-guided-strategies-to-improve-recognition-diagnosis-and-treatment-of-ph-associated-with-ild-1

These educational podcasts will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.Launch Date: October 10, 2024Release Date: October 10, 2024Expiration Date: September 30, 2025FACULTYIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/independent-conference-coverage-from-the-american-college-of-chest-physicians-chest-annual-meeting-2024-1

These educational podcasts will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.Launch Date: October 10 2024Release Date: October 10, 2024Expiration Date: September 30, 2025FACULTYIoana Preston, MDAssociate Professor of MedicineTufts University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/independent-conference-coverage-from-the-american-college-of-chest-physicians-chest-annual-meeting-2024-1

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.Launch Date: October 3 2024Release Date: October 3, 2024Expiration Date: September 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityCaitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.Launch Date: October 1, 2024Release Date: October 1, 2024Expiration Date: September 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityCaitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this podcast episode, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.Launch Date: September 4, 2024Release Date: September 4, 2024Expiration Date: August 31, 2025FACULTYRonald J. Oudiz, MD, FACP, FACC, FCCPChief, Division of CardiologyProfessor of MedicineThe David Geffen School of Medicine at UCLADirector, Pulmonary Hypertension ClinicHarbor-UCLA Medical CenterTeresa De Marco, MDProfessor of Medicine; R.H. and Jane G. Logan Endowed Chair in CardiologyUniversity of California, San FranciscoMedical Director Heart TransplantationBurlingame, CaliforniaThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/talking-pah-navigating-clinical-challenges-through-case-studies-of-complex-scenarios-12

This podcast features an engaging discussion between Dr. Douglas Dieterich and his patient, a 54-year-old woman with long-standing PBC, on the patient's insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: August 21, 2024Release Date: August 21, 2024Expiration Date: July 31, 2025FACULTYDouglas Dieterich, MDDirector, Institute for Liver Medicine at Mount SinaiProfessor of Medicine, Icahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

Estimated to impact at least 125 million people worldwide, the burden of living with psoriasis runs more than skin deep. From the physical impact and comorbidities to the emotional toll that may plague everyday life, many patients still struggle with inadequate disease control, often going untreated or undertreated, despite the myriad treatment options available. There is a significant need for new psoriasis treatment options, and this interactive program is designed to provide expert interpretation of new and emerging data on the treatment of psoriasis, with multidisciplinary expert perspectives on how new agents can impact clinical practice. This podcast will discuss how to help clinicians select the most appropriate treatment as well as address the significant health burdens and comorbidities experienced by many patients with psoriasis.Launch Date: August 15, 2024Release Date: August 15, 2024Expiration Date: July 31, 2025FACULTYBruce Strober, MD, PhDClinical ProfessorYale University and Central Connecticut UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/optimizing-outcomes-in-psoriasis-exploring-the-impact-of-rapid-diagnosis-and-emerging-therapeutic-agents

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' videos from data presented during the 25th International AIDS Conference.Launch Date: August 1, 2024Release Date: August 1, 2024Expiration Date: July 31, 2025FACULTYPaul Sax, MDClinical DirectorDivision of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-25th-international-aids-conference-aids-2024-1

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' videos from data presented during the 25th International AIDS Conference.Launch Date: August 1, 2024Release Date: August 1, 2024Expiration Date: July 31, 2025FACULTYPaul Sax, MDClinical DirectorDivision of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-25th-international-aids-conference-aids-2024-1

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' videos from data presented during the 25th International AIDS Conference.Launch Date: August 1, 2024Release Date: August 1, 2024Expiration Date: July 31, 2025FACULTYPaul Sax, MDClinical DirectorDivision of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-25th-international-aids-conference-aids-2024-1

Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know' videos from data presented during the 25th International AIDS Conference.Launch Date: August 1, 2024Release Date: August 1, 2024Expiration Date: July 31, 2025FACULTYPaul Sax, MDClinical DirectorDivision of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-hiv-independent-coverage-from-the-25th-international-aids-conference-aids-2024-1

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.Launch Date: July 26, 2024Release Date: July 26, 2024Expiration Date: June 30, 2025FACULTYTimothy Craig, DO, FAAAAI, FACP, FACAAI, FACOITenured Professor of MedicinePediatrics and Distinguished EducatorPennsylvania State UniversityMarc Riedl, MD, MSProfessor of MedicineUniversity of California, San DiegoClinical Director - US HAEA Angioedema CenterUniversity of California, San DiegoThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-centered-approaches-to-long-term-prophylaxis-in-hae-1

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA 2024) Hybrid Congress, June 13-16, Madrid, Spain.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector of the Center of Excellencefor Blood Cancers and Myeloid DisordersNew York, New YorkThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcast-from-eha-2024-advancements-in-myelofibrosis-from-pathophysiology-to-personalized-treatment-strategies

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioPeter Voorhees, MDClinical Professor, Hematology and OncologyWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/podcasts-in-advanced-newly-diagnosed-multiple-myeloma-updates-from-eha-2024

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the EHA 2024 Hybrid Congress, June 13-16, Madrid, Spain.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025FACULTYCindy Neunert, MDAssociate Professor of PediatricsColumbia University Irving Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcasts-in-pediatric-itp-advancements-in-pediatric-itp-management-insights-from-eha-2024

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit. Launch Date: June 11, 2024 Release Date: June 11, 2024Expiration Date: May 31, 2025 Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.  https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit. Launch Date: June 11, 2024 Release Date: June 11, 2024Expiration Date: May 31, 2025 Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.  https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis

This is an accredited continuing education podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.Launch Date: June 5, 2024Release Date: June 5, 2024Expiration Date: May 31, 2025FACULTY BIOStephen Liu, MDAssociate Professor of MedicineDirector of Thoracic OncologyDirector of Developmental TherapeuticsLombardi Comprehensive Cancer CenterGeorgetown UniversityThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/podcasts-in-nsclc-harboring-egfr-mutations-cutting-edge-reports-from-asco-2024